Keyword search
Filter results by
Search HelpKeyword(s)
Subject
Survey or statistical program
Results
All (6)
All (6) ((6 results))
- Articles and reports: 88-003-X20030016474Geography: Canada, Province or territoryDescription:
In 2001, there were 375 biotechnology innovator firms in Canada, an increase of just under 5% from the 358 firms in 1999. Analysis beyond these overall statistics discloses a dynamic churning that is occurring among sectors, provinces and size groups.
Release date: 2003-02-18 - 2. Coming of age - biotech revenues are on the rise ArchivedArticles and reports: 88-003-X20030016476Geography: CanadaDescription:
Canadian biotechnology is gaining momentum. More firms are getting their products onto the markets and increasing revenues. With the human health sector leading the way, biotechnology revenues rose by a massive 343% for the 1997 to 2001 period, reaching $3.5 billion in 2001. During this same period, the number of firms increased by 33%.
Release date: 2003-02-18 - Articles and reports: 88F0006X2002004Description:
Spin-off firms made up over 34% of the core group of firms from the 1999 biotechnology survey. They also made up over 112 of the 270 small (under 50 employees) size firms, by far the largest group of core biotechnology, and half of the human health related firms, the largest sector of biotechnology firms. Central to this paper is the question: What are the general characteristics of this sub-group of core biotechnology firms?
Release date: 2002-03-28 - 4. Canadian Biotechnology Industrial Activities: Features from the 1997 Biotechnology Survey ArchivedArticles and reports: 88F0006X2001012Description:
As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.
Release date: 2001-09-25 - Articles and reports: 88F0006X2001011Description:
This paper provides a summary of the strategies and business practices of biotechnology firms, and information on the business environment faced by these firms. These issues, considered in conjunction with information on revenue, research and development, import and export, product pipeline and human resources characteristics of biotechnology firms, contribute to a more comprehensive portrait of the biotechnology sector in Canada.
Release date: 2001-08-28 - Articles and reports: 88-003-X20010025752Geography: CanadaDescription:
With revenues of almost $2 billion, what are the characteristics and activities of firms that use or develop biotechnology as an important part of their firm's activities? Human Health biotechnology dominates both the revenue and spending in the biotechnology sector. Read this enlightening article for further details including dicussion on the geographic location and size of Canadian biotechnology firms.
Release date: 2001-05-02
Data (0)
Data (0) (0 results)
No content available at this time.
Analysis (6)
Analysis (6) ((6 results))
- Articles and reports: 88-003-X20030016474Geography: Canada, Province or territoryDescription:
In 2001, there were 375 biotechnology innovator firms in Canada, an increase of just under 5% from the 358 firms in 1999. Analysis beyond these overall statistics discloses a dynamic churning that is occurring among sectors, provinces and size groups.
Release date: 2003-02-18 - 2. Coming of age - biotech revenues are on the rise ArchivedArticles and reports: 88-003-X20030016476Geography: CanadaDescription:
Canadian biotechnology is gaining momentum. More firms are getting their products onto the markets and increasing revenues. With the human health sector leading the way, biotechnology revenues rose by a massive 343% for the 1997 to 2001 period, reaching $3.5 billion in 2001. During this same period, the number of firms increased by 33%.
Release date: 2003-02-18 - Articles and reports: 88F0006X2002004Description:
Spin-off firms made up over 34% of the core group of firms from the 1999 biotechnology survey. They also made up over 112 of the 270 small (under 50 employees) size firms, by far the largest group of core biotechnology, and half of the human health related firms, the largest sector of biotechnology firms. Central to this paper is the question: What are the general characteristics of this sub-group of core biotechnology firms?
Release date: 2002-03-28 - 4. Canadian Biotechnology Industrial Activities: Features from the 1997 Biotechnology Survey ArchivedArticles and reports: 88F0006X2001012Description:
As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.
Release date: 2001-09-25 - Articles and reports: 88F0006X2001011Description:
This paper provides a summary of the strategies and business practices of biotechnology firms, and information on the business environment faced by these firms. These issues, considered in conjunction with information on revenue, research and development, import and export, product pipeline and human resources characteristics of biotechnology firms, contribute to a more comprehensive portrait of the biotechnology sector in Canada.
Release date: 2001-08-28 - Articles and reports: 88-003-X20010025752Geography: CanadaDescription:
With revenues of almost $2 billion, what are the characteristics and activities of firms that use or develop biotechnology as an important part of their firm's activities? Human Health biotechnology dominates both the revenue and spending in the biotechnology sector. Read this enlightening article for further details including dicussion on the geographic location and size of Canadian biotechnology firms.
Release date: 2001-05-02
Reference (0)
Reference (0) (0 results)
No content available at this time.
- Date modified: